Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07548489 · ClinicalTrials.gov registry record · Phase 3
Phenobarbital for Agitated Delirium
A Phase 3 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07548489 is a Phase 3 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 150 participants.
The verdict
NCT07548489, a Phase 3 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether the medication phenobarbital is as effective for treating agitated delirium among adult patients admitted to the intensive care unit. Agitated delirium is a condition involving confusion and impulsiveness which is dangerous to both patients and healthcare providers. The main questions this trial aims to answer include: * Can phenobarbital decrease the amount of time patients with agitated delirium spend in the intensive care unit and the hospital? * Does phenobarbital decrease the amount of additional calming medications patients with agitated delirium need? Researchers in this study will compare phenobarbital to other medications commonly used to treat agitated delirium. Participants will be monitored closely to make sure they remain safe and to measure how well their agitation and confusion are managed while they are in the ICU.
Interventions
- DRUG Phenobarbital
- DRUG Conventional therapy group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07548489
The ClinicalTrials.gov registry entry for NCT07548489 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phenobarbital is the first listed.
NCT07548489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07548489 about?
NCT07548489 is a clinical study titled "Phenobarbital for Agitated Delirium". The goal of this clinical trial is to test whether the medication phenobarbital is as effective for treating agitated delirium among adult patients admitted to the intensive care unit. Agitated delirium is a condition involving confusion and impulsiveness which is dangerous to both patients and heal...
What is the current status of trial NCT07548489?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07548489?
The interventions under investigation include: Phenobarbital (DRUG), Conventional therapy group (DRUG).
Who is sponsoring clinical trial NCT07548489?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.